Category: Health & Finance
Hims & Hers Health shares fell 20.4% after the FDA announced the end of shortages for Novo Nordisk's weight loss drugs, impacting Hims & Hers' compounded semaglutide sales. The company is focused on expanding its infrastructure and has purchased a peptide plant in California to enhance its domestic supply chain for customized drugs, aiming for better control over product availability and quality.
Keywords: Hims & Hers, FDA, Novo Nordisk
Update At: 2/22/2025